Literature DB >> 22061202

Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases.

Fabio Sambataro1, Maria Pennuto.   

Abstract

Polyglutamine diseases are neurodegenerative disorders caused by expansion of polyglutamine tracts in the coding regions of specific genes. One of the most important features of polyglutamine diseases is that, despite the widespread and in some cases ubiquitous expression of the polyglutamine proteins, specific populations of neurons degenerate in each disease. This finding has led to the idea that polyglutamine diseases are cell-autonomous diseases, in which selective neuronal dysfunction and death result from damage caused by the mutant protein within the targeted neuronal population itself. Development of animal models for conditional expression of polyglutamine proteins, along with new pharmacologic manipulation of polyglutamine protein expression and toxicity, has led to a remarkable change of the current view of polyglutamine diseases as cell-autonomous disorders. It is becoming evident that toxicity in the neighboring non-neuronal cells contributes to selective neuronal damage. This observation implies non-cell-autonomous mechanisms of neurodegeneration in polyglutamine diseases. Here, we describe cell-autonomous and non-cell-autonomous mechanisms of polyglutamine disease pathogenesis, including toxicity in neurons, skeletal muscle, glia, germinal cells, and other cell types.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22061202     DOI: 10.1016/j.pneurobio.2011.10.003

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  18 in total

Review 1.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 2.  Advances in reprogramming-based study of neurologic disorders.

Authors:  Anjana Nityanandam; Kristin K Baldwin
Journal:  Stem Cells Dev       Date:  2015-04-06       Impact factor: 3.272

3.  Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy.

Authors:  Christian M Simon; Ya Dai; Meaghan Van Alstyne; Charalampia Koutsioumpa; John G Pagiazitis; Joshua I Chalif; Xiaojian Wang; Joseph E Rabinowitz; Christopher E Henderson; Livio Pellizzoni; George Z Mentis
Journal:  Cell Rep       Date:  2017-12-26       Impact factor: 9.423

4.  Investigating the spreading and toxicity of prion-like proteins using the metazoan model organism C. elegans.

Authors:  Carmen I Nussbaum-Krammer; Mário F Neto; Renée M Brielmann; Jesper S Pedersen; Richard I Morimoto
Journal:  J Vis Exp       Date:  2015-01-08       Impact factor: 1.355

5.  Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.

Authors:  Wooi F Lim; Mitra Forouhan; Thomas C Roberts; Jesse Dabney; Ruth Ellerington; Alfina A Speciale; Raquel Manzano; Maria Lieto; Gavinda Sangha; Subhashis Banerjee; Mariana Conceição; Lara Cravo; Annabelle Biscans; Loïc Roux; Naemeh Pourshafie; Christopher Grunseich; Stephanie Duguez; Anastasia Khvorova; Maria Pennuto; Constanza J Cortes; Albert R La Spada; Kenneth H Fischbeck; Matthew J A Wood; Carlo Rinaldi
Journal:  Sci Adv       Date:  2021-08-20       Impact factor: 14.136

Review 6.  Skeletal Muscle Pathogenesis in Polyglutamine Diseases.

Authors:  Caterina Marchioretti; Emanuela Zuccaro; Udai Bhan Pandey; Jessica Rosati; Manuela Basso; Maria Pennuto
Journal:  Cells       Date:  2022-07-03       Impact factor: 7.666

Review 7.  In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Manuela Basso
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

8.  Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.

Authors:  Biswarathan Ramani; Bharat Panwar; Lauren R Moore; Bo Wang; Rogerio Huang; Yuanfang Guan; Henry L Paulson
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

Review 9.  More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases.

Authors:  Justin G Boyer; Andrew Ferrier; Rashmi Kothary
Journal:  Front Physiol       Date:  2013-12-18       Impact factor: 4.566

10.  Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Carlo Rinaldi; Laura C Bott; Ke-lian Chen; George G Harmison; Masahisa Katsuno; Gen Sobue; Maria Pennuto; Kenneth H Fischbeck
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.